![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York
We hypothesize that superoxide (
) accumulation is not a crucial causative factor in inducing nitroglycerin (NTG) tolerance. In LLC-PK1 cells, pre-exposure to NTG resulted in increased
accumulation and reduced cGMP response to NTG versus vehicle control.
stimulated by NTG was reduced by oxypurinol (100 µM), a xanthine oxidase inhibitor. Exposure to angiotensin II (Ang II) increased
but did not reduce cGMP response. The
scavenger tiron reduced Ang II-induced
production but did not increase NTG-stimulated cGMP production. Using p47phox–/– and gp91phox–/– mice versus their respective wild-type controls (WT), we showed that aorta from mice null of these critical NADPH oxidase subunits exhibited similar vascular tolerance after NTG dosing (20 mg/kg s.c., t.i.d. for 3 days), as indicated by their ex vivo pEC50 and cGMP accumulation upon NTG challenge. In vitro aorta
production was enhanced by NTG incubation in both p47phox null and WT mice. Pre-exposure of isolated mice aorta to 100 µM NTG for 1 h resulted in vascular tolerance toward NTG and increased
accumulation. Oxypurinol (1 mM) reduced
but did not attenuate vascular tolerance. These results suggest that
does not initiate either in vitro and in vivo NTG tolerance, and that the p47phox and gp91phox subunits of NADPH oxidase are not critically required. Increased
accumulation may be an effect, rather than an initiating cause, of NTG tolerance.
Address correspondence to: Dr. Ho-Leung Fung, Hochstetter 547, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14260-1200. E-mail: hlfung{at}buffalo.edu
This article has been cited by other articles:
![]() |
P.-S. Tsou, V. Addanki, J. A. Haas, N. A. Page, and H.-L. Fung Role of Glutaredoxin-Mediated Protein S-Glutathionylation in Cellular Nitroglycerin Tolerance J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 649 - 656. [Abstract] [Full Text] [PDF] |
||||